Your browser doesn't support javascript.
loading
Controlled Release of Doxorubicin for Targeted Chemo-Photothermal Therapy in Breast Cancer HS578T Cells Using Albumin Modified Hybrid Nanocarriers.
Carrese, Barbara; Cavallini, Chiara; Sanità, Gennaro; Armanetti, Paolo; Silvestri, Brigida; Calì, Gaetano; Pota, Giulio; Luciani, Giuseppina; Menichetti, Luca; Lamberti, Annalisa.
Afiliação
  • Carrese B; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
  • Cavallini C; Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
  • Sanità G; Institute of Applied Sciences and Intelligent Systems, National Research Council, 80078 Naples, Italy.
  • Armanetti P; Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
  • Silvestri B; Department of Chemical, Materials and Production Engineering, University of Naples Federico II, 80125 Naples, Italy.
  • Calì G; Institute of Endocrinology and Experimental Oncology, National Research Council, 80131 Naples, Italy.
  • Pota G; Department of Chemical, Materials and Production Engineering, University of Naples Federico II, 80125 Naples, Italy.
  • Luciani G; Department of Chemical, Materials and Production Engineering, University of Naples Federico II, 80125 Naples, Italy.
  • Menichetti L; Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
  • Lamberti A; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Int J Mol Sci ; 22(20)2021 Oct 18.
Article em En | MEDLINE | ID: mdl-34681890
ABSTRACT
Hybrid nanomaterials have attracted research interest owing to their intriguing properties, which may offer new diagnostic options with triggering features, able to realize a new kind of tunable nanotherapeutics. Hybrid silica/melanin nanoparticles (NPs) containing silver seeds (Me-laSil_Ag-HSA NPs) disclosed relevant photoacoustic contrast for molecular imaging. In this study we explored therapeutic function in the same nanoplatform. For this purpose, MelaSil_Ag-HSA were loaded with doxorubicin (DOX) (MelaSil_Ag-HSA@DOX) and tested to assess the efficiency of drug delivery combined with concurrent photothermal treatment. The excellent photothermal properties allowed enhanced cytotoxic activity at significantly lower doses than neat chemotherapeutic treatment. The results revealed that MelaSil_Ag-HSA@DOX is a promising platform for an integrated photothermal (PT) chemotherapy approach, reducing the efficacy concentration of the DOX and, thus, potentially limiting the several adverse side effects of the drug in in vivo treatments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Portadores de Fármacos / Doxorrubicina / Sistemas de Liberação de Medicamentos / Albuminas / Nanopartículas / Terapia Fototérmica Limite: Female / Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Portadores de Fármacos / Doxorrubicina / Sistemas de Liberação de Medicamentos / Albuminas / Nanopartículas / Terapia Fototérmica Limite: Female / Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article